BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37276138)

  • 1. The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.
    Geurs S; Clarisse D; De Bosscher K; D'hooghe M
    J Med Chem; 2023 Jun; 66(12):7698-7729. PubMed ID: 37276138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
    Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc binding groups for histone deacetylase inhibitors.
    Zhang L; Zhang J; Jiang Q; Zhang L; Song W
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):714-721. PubMed ID: 29616828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
    Choi SE; Weerasinghe SV; Pflum MK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
    J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
    Patil V; Sodji QH; Kornacki JR; Mrksich M; Oyelere AK
    J Med Chem; 2013 May; 56(9):3492-506. PubMed ID: 23547652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational exploration of zinc binding groups for HDAC inhibition.
    Chen K; Xu L; Wiest O
    J Org Chem; 2013 May; 78(10):5051-5. PubMed ID: 23586590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
    Yue K; Qin M; Huang C; James Chou C; Jiang Y; Li X
    Bioorg Med Chem Lett; 2022 Aug; 70():128797. PubMed ID: 35580726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
    Choi SE; Pflum MK
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
    Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
    Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
    Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
    Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
    Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
    Hendricks JA; Keliher EJ; Marinelli B; Reiner T; Weissleder R; Mazitschek R
    J Med Chem; 2011 Aug; 54(15):5576-82. PubMed ID: 21721525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.
    Labisso WL; Wirth M; Stojanovic N; Stauber RH; Schnieke A; Schmid RM; Krämer OH; Saur D; Schneider G
    Cell Cycle; 2012 Apr; 11(8):1593-602. PubMed ID: 22456335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.